Streetbeat News

Price Targets

FTAI

RBC Capital analyst Ken Herbert maintains an Outperform rating on FTAI Aviation and raises the price target from $120 to $143.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 1:12 pm

CASY

JP Morgan analyst John Royall has downgraded Casey's General Stores from Neutral to Underweight, while raising the price target from $300 to $337.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 1:11 pm

MUSA

JP Morgan analyst John Royall has downgraded Murphy USA from Neutral to Underweight, while raising the price target from $415 to $435.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 1:10 pm

PGNY

Leerink Partners has maintained a Market Perform rating on Progyny (NASDAQ:PGNY) but lowered its price target from $25 to $21, indicating a more cautious outlook.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 1:09 pm

HALO

JP Morgan analyst Jessica Fye has downgraded Halozyme Therapeutics from Overweight to Neutral, while raising the price target from $52 to $57.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 1:08 pm

AGIO

RBC Capital analyst Gregory Renza has reiterated an Outperform rating for Agios Pharmaceuticals, maintaining a price target of $55.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 1:08 pm

FIVE

JP Morgan analyst Matthew Boss has downgraded Five Below (NASDAQ:FIVE) from Neutral to Underweight, while raising the price target from $89 to $95.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 1:05 pm

FDMT

Leerink Partners has reiterated its Outperform rating for 4D Molecular Therapeutics (NASDAQ:FDMT) but lowered the price target from $40 to $36.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 1:05 pm

ALNY

RBC Capital analyst Luca Issi has reiterated an Outperform rating for Alnylam Pharmaceuticals, maintaining a price target of $300.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 1:04 pm

APLT

Leerink Partners has maintained an 'Outperform' rating on Applied Therapeutics (NASDAQ:APLT) and raised the price target from $11 to $14, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 1:01 pm